NYSEArca - Delayed Quote USD

Financial Select Sector SPDR Fund (XLF)

41.12 -0.01 (-0.02%)
At close: April 24 at 4:00 PM EDT
41.17 +0.05 (+0.12%)
Pre-Market: 6:29 AM EDT
Loading Chart for XLF
DELL
  • Previous Close 41.13
  • Open 41.02
  • Bid 40.99 x 29200
  • Ask 41.20 x 38500
  • Day's Range 40.92 - 41.17
  • 52 Week Range 31.26 - 42.22
  • Volume 33,302,165
  • Avg. Volume 47,292,754
  • Net Assets 38.44B
  • NAV 41.11
  • PE Ratio (TTM) 18.66
  • Yield 1.52%
  • YTD Daily Total Return 9.77%
  • Beta (5Y Monthly) 1.03
  • Expense Ratio (net) 0.09%

The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Financial companies by the Global Industry Classification Standard, including securities of companies from the following industries: financial services; insurance; banks; capital markets; mortgage real estate investment trusts; and consumer finance. The fund is non-diversified.

SPDR State Street Global Advisors

Fund Family

Financial

Fund Category

38.44B

Net Assets

1998-12-16

Inception Date

Performance Overview: XLF

Trailing returns as of 4/24/2024. Category is Financial.

YTD Return

XLF
9.77%
Category
7.57%
 

1-Year Return

XLF
26.28%
Category
27.76%
 

3-Year Return

XLF
7.13%
Category
5.12%
 

People Also Watch

Holdings: XLF

Top 10 Holdings (54.74% of Total Assets)

SymbolCompany% Assets
BRK-B
Berkshire Hathaway Inc. 13.18%
JPM
JPMorgan Chase & Co. 9.98%
V
Visa Inc. 7.60%
MA
Mastercard Incorporated 6.85%
BAC
Bank of America Corporation 4.50%
WFC
Wells Fargo & Company 3.60%
SPGI
S&P Global Inc. 2.36%
GS
The Goldman Sachs Group, Inc. 2.35%
AXP
American Express Company 2.24%
PGR
The Progressive Corporation 2.09%

Sector Weightings

SectorXLF
Technology   3.01%
Industrials   0.60%
Real Estate   0.00%
Utilities   0.00%
Energy   0.00%
Healthcare   0.00%

Recent News: XLF

Research Reports: XLF

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • Analyst Report: Netflix, Inc.

    Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.

    Rating
    Price Target
     
  • Analyst Report: Meta Platforms, Inc.

    Meta is the world’s largest online social network, with nearly 4 billion family of apps monthly active users. Users engage with each other in different ways, exchanging messages and sharing news events, photos, and videos. The firm’s ecosystem consists mainly of the Facebook app, Instagram, Messenger, WhatsApp, and many features surrounding these products. Users can access Facebook on mobile devices and desktops. Advertising revenue represents more than 90% of the firm’s total revenue, with more than 45% coming from the U.S. and Canada and over 20% from Europe.

    Rating
    Price Target
     
  • Analyst Report: Amazon.com, Inc.

    Amazon is a leading online retailer and one of the highest-grossing e-commerce aggregators, with $386 billion in net sales and approximately $578 billion in estimated physical/digital online gross merchandise volume in 2021. Retail-related revenue represents approximately 80% of the total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (10%-15%), advertising services (5%), and other. International segments constitute 25%-30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.

    Rating
    Price Target
     

Related Tickers